SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novacare (NOV) breaking out... -- Ignore unavailable to you. Want to Upgrade?

To: Yuppy who wrote (251)2/27/1998 3:34:00 PM
From: Todd D. Wiener  Respond to of 420
 
Yuppy-

Although the market may not respond this way, every $3 that NCES rises, NOV SHOULD rise $1. This is true because of NOV's ownership of NCES. But NOV could rise to $20 and NCES wouldn't be worth any more than it currently is.

Summary: Large movements in NCES can move NOV, but NOV can't move NCES.

Todd



To: Yuppy who wrote (251)3/20/1998 4:54:00 PM
From: Todd D. Wiener  Read Replies (3) | Respond to of 420
 
NCES is in full breakout/rally mode, with resistance at $8 and $9.50. NOV has dipped in the past few days, for no apparent reason. I see the drop as a buying opportunity for those who are interested.

I have year-end price targets of $12 for NCES and $20 for NOV.

Todd


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News